Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

20065,762 citationsJournal Articlebronze Open Access

Authors

Alan Sandler · Vanderbilt University

Robert J. Gray · Dana-Farber Cancer Institute

Michael C. Perry · University of Missouri

Julie R. Brahmer · Johns Hopkins University

Joan H. Schiller · University of Wisconsin–Madison

Afshin Dowlati · University Hospitals of Cleveland

Rogério Lilenbaum

Abstract

The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Topics & Keywords

Peptidase Inhibition and Analysis Lung Cancer Treatments and Mutations PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 24, pp. 2542-2550

DOI: 10.1056/nejmoa061884

Field-Weighted Citation Impact: 154.49